Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Fluorouracil + Liposomal irinotecan + SHR-1316 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Fluorouracil | Adrucil | 5-FU|5-Fluorouracil | Chemotherapy - Antimetabolite 14 | Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent that interferes with DNA and RNA synthesis, thereby preventing cancer cell growth (PMID: 28520376). Adrucil (fluorouracil) is FDA-approved for use in patients with adenocarcinoma of the colon, rectum, breast, stomach, and pancreas (FDA.gov). |
| Liposomal irinotecan | Onivyde | PEP02|nal-IRI|MM-398|Irinotecan Sucrosofate | TOPO1 inhibitor 11 | Onivyde (liposomal irinotecan) comprises irinotecan encapsulated in liposomal nanoparticles, which may result in increased tumor growth inhibition (PMID: 23406728, PMID: 16540680, PMID: 29945562). Onivyde (liposomal irinotecan) in combination with chemotherapy is FDA-approved for use in patients with metastatic pancreatic adenocarcinoma (FDA.gov). |
| SHR-1316 | SHR 1316|SHR1316|Adebrelimab|HTI 1088|HTI-1088|HTI1088 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 136 | SHR-1316 is a monoclonal antibody that targets PD-L1 (CD274), potentially resulting in antitumor activity (PMID: 33760397). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|